1887
Volume 2009, Issue 1
  • ISSN: 0253-8253
  • E-ISSN: 2227-0426

Abstract

Background: Since some patients with psoriatic arthritis do not respond to typical drug treatments, alternatives are needed. Findings suggest that interleukins 12 and 23 might affect clinical symptoms and pathological joint changes of psoriatic arthritis. Ustekinumab is a human monoclonal antibody that inhibits receptor-binding of these cytokines. We aimed to assess the efficacy and safety of ustekinumab for psoriatic arthritis in this phase II study.

Loading

Article metrics loading...

/content/journals/10.5339/qmj.2009.1.26
2009-05-01
2019-10-22
Loading full text...

Full text loading...

http://instance.metastore.ingenta.com/content/journals/10.5339/qmj.2009.1.26
Loading
  • Article Type: Abstract
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error